about
Abiraterone and increased survival in metastatic prostate cancerVaccine and Antibody Treatment of Prostate CancerSequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate CancerFerumoxytol Enhanced MRI for the Detection of Lymph Node Involvement in Prostate CancerStudy of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on TherapyA Phase 1 Clinical Trial of ARV-110 in Patients With Metastatic Castration-resistant Prostate Cancer.Feasibility of a Chemotherapy With Docetaxel-Prednisone for Castration-resistant Metastatic Prostate Cancer Elderly PatientsStudy of 18F-DCFPyL, a Second Generation Low-molecular Weight PSMA-based PET Radiotracer, in Patients With Prostate CancerCabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate CancerImpact of New Generation Hormono-therapy on Cognitive Functions in Elderly Patients Treated for a Metastatic Prostate CancerA Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostate Cancer and Men With Metastatic Prostate CanPET/MR Assessment of Sipuleucel T Treatment for Metastatic Castration Resistant Prostate CancerAbiraterone Race in Metastatic Castrate-resistant Prostate CancerEnzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate CancerAbiraterone Acetate in Combination With Docetaxel After Disease Progression to Abiraterone Acetate in Metastatic Castration Resistant Prostate Cancer.Evaluation of 18F-DCFBC PSMA-based PET Imaging for Detection of Metastatic Prostate CancerA Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)Second-line Chemotherapy in Castration Resistant Prostate CancerPazopanib, Docetaxel, Prednisone ProstateAbiraterone Acetate Trial in African American Prostate Cancer PatientsA Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate CancerProstate Cancer Prospective CohortGenomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate CancerPhase IIB Clinical Trial of Hamsa-1™ in Metastatic Castration Resistant Prostate Cancer (CRPC)Observational Study of Docetaxel Exposure in Metastatic Prostate Cancer PatientsLocal Treatment With RP for Newly-diagnosed mPCaA Study in Patients With Metastatic Prostate Cancer to Assess How the Drug Eligard®, Affects Certain Markers in Blood and Urine, Which Are Indicators for the DiseaseEnzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate CancerA Study of Abiraterone Acetate Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate CancerA Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)A Two-dose Level Clinical Trial of Itraconazole in Patients With Metastatic Prostate Cancer Who Have Had Disease Progression While on Hormonal TherapyMetronomic Oral Vinorelbine in Patients With Metastatic TumorsEstramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the ProstateDocetaxel and Diethylstilbestrol in the Treatment of Androgen Independent Prostate CancerA Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate CancerA Phase 2 Study of Trabectedin (Yondelis) in Adult Male Participants With Advanced Prostate CancerA Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate CancerPhase I Trial of PACE for Metastatic Prostate CancerHydroxychloroquine to Increase Tumor Suppressor PAR-4 Levels in Oligometastatic Prostate CancerA Phase 1 Trial for Evaluation of the Safety, Pharmacokinetics, and [18F] Radiation Dosimetry of CTT1057
P921
Q29617512-bdf8d48e-4733-ba49-0823-feaf59e4ed78Q61865309-1DAC2D40-0494-4D0D-896C-AADD5DCD70B0Q63012565-918813CF-6EC3-41ED-80C8-2C993FC249E2Q63339123-BB06E763-E76E-4013-BEF9-E6D27E2C2160Q63404222-35068A43-BD42-4FB0-A772-8B35D99C8653Q63581121-4794A82F-0DD6-4FEF-BA5C-BD51B689593BQ63818399-2FFA5CC6-92A6-4316-89D9-4498E5A69873Q64139612-22941541-8B3F-4079-9465-9E0F0D1DE5B2Q64170814-9B60ABB8-706C-427B-A715-62FE23126154Q64186960-7FAAA171-2AB6-4182-A3ED-AF6F991E0315Q64222983-B1F8AC21-AB42-4462-B549-24F1C2819DBCQ64348851-4A5E6980-5C58-454F-B3D6-80E573AE7D4DQ64354956-0EFEA732-AD4F-446B-953D-C39134428BFDQ64395963-9D51F55E-85CF-4833-9724-B9004D80CEF0Q64397427-05099B35-B000-452A-8407-D0B9996A281DQ64631572-944A8845-FB10-41ED-83EA-4C8A8F357D85Q64639455-DAD805E0-A84F-48FC-A6C6-2707675EF4C4Q64645319-AFBC5C3E-1B75-4B64-8323-0397AC3E9820Q64649606-A5B12ADF-ACC7-4987-9156-36219D907061Q64650987-85CD0CED-1A17-4C6E-8D04-4BB1AF97DF18Q64665661-58FE4C34-A6D6-45F5-AB02-CB30A0CB244DQ64673147-129ECBEB-1C62-4DF7-A34A-7129428E9932Q64677092-7AD3EC9C-78D9-47EA-9F3D-C34AC64C5B6EQ64719361-64C7E42D-D522-4922-AFE7-D0D78033A15BQ65347002-4F98D163-4AAF-4F9C-BE71-37DA26774EC2Q65358038-96873F3D-5FD8-40A3-B13E-F1414781B413Q65359881-4D3ED3DB-07AB-4B8B-A8DB-480B9A6F4A61Q65360009-FC6DBDDA-5AD5-4A8E-9388-C9CEAE4A92F6Q65367921-7F6D413C-22A1-44F4-90E1-6D564793B7DDQ65387121-C95E8178-2E36-4598-8F7B-0DEC39F8B02DQ65536362-E5339B05-F521-4708-8A6B-96E82753A5A7Q65538996-54D433B2-430F-4992-99A9-71A3352C2B18Q66028522-287E763B-50A4-4593-AB6F-849B13D1D880Q66029296-DB0AD749-F3AE-4DC2-9FF0-09A730870FD6Q66032915-4098FD6E-2AD4-431D-A407-7984896E6868Q66034152-A608820B-0062-46C4-A6FE-6F04F6966EDBQ66037218-3030882E-034B-492B-A07D-6C888231F946Q66047068-6E6241B5-D5D9-4927-A26F-0C66EA472884Q66062805-06611D41-FCDF-459A-A4CA-188A031BCBF4Q66080384-7C6603FE-AFCF-48BA-B9F1-A517A322457A
P921
description
carcinoma that arises from the prostate gland and has spread to other anatomic sites
@en
name
carcinome métastatique de la prostate
@fr
metastatic prostate carcinoma
@en
type
label
carcinome métastatique de la prostate
@fr
metastatic prostate carcinoma
@en
altLabel
Metastatic Prostate Cancer
@en
Metastatic Prostate Carcinoma
@en
Prostate Cancer Metastatic
@en
Prostate Carcinoma Metastatic
@en
prefLabel
carcinome métastatique de la prostate
@fr
metastatic prostate carcinoma
@en
P1692
P1748
P2892
P5270
MONDO:0004956